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Abstract - Genetic testing for potentially 
heritable cardiomyopathies has advanced from basic 
scientific discovery to clinical application. 
Nowadays, genetic diagnostic tests for 
cardiomyopathies are clinically available. As a 
consequence is fundamental the understanding of the 
clinical utility, in terms of diagnosis and prognosis, 
of genetic test results. In addition, the genetic 
counselling, regarding risks, benefits and options, is 
recommended for all patients and their relatives. 
However the relation between genotype and 
phenotype remains often unclear, and there is 
frequently a variance of uncertain significance. 
Consequently, the genetic test should always be 
approached as one component of a comprehensive 
cardio-genetic evaluation. 
This review aims to explore when genetic tests 
are indicated in patients with dilated and 
hypertrophic cardiomyopathy. 
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 The first gene-mutation causing cardiomyopathy 
was discovered more than thirty years ago. Nowadays the 
genic-mutations are at least 500 just for Hypertrophic 
Cardiomyopathy. However, the clinical beneficial of a 
genetic-test result remains often unclear and questionable. 
Usually, the first approach to a patient with a 
cardiomyopathy is guided by the phenotype. Anamnesis 
and instrumental investigations, and above all 
electrocardiography and echocardiography, areextremely 
useful.Another diagnostic investigation, performed in 
specialized centres,is magnetic resonance imaging (MRI). 
It is very important to characterize the muscle tissue and 
the interstitial space. A detailed family history could guide 
the diagnosis of a familial genetic disease, although there 
is the possibility of a de novo mutation that should be 
suspected in the absence of a positive family history for 
disease. Different mutations in the same gene might cause 
different disease phenotype and different disease severity. 
For example laminin A/C mutations might cause isolated 
Dilated Cardiomyopathy (DCM), Emery-Dreifuss 
Muscular Dystrophy, or disorders without DCM. 
Cardiologists should know the feasibility of a genetic 
diagnosis, its clinical relevance and its potential impact on 
prognosis. Another fundamental aspect is the genetic 
counselling, finalized to discuss the significance of the 
identification of the genetic mutation with the patient and 
its relevance in his/her life. Contrary to common 
misperception, genetic tests are probabilistic and not 
deterministic tests. Many positive tests are represented by 
DNA variants of uncertain clinical significance. The 
genetic testing for cardiomyopathies has some ethical 
problems: is it right to consider sick a patient with a 
mutation indicative of disease if he might never show the 
phenotype? 
 
II.  DILATATED CARDIOMYOPATHY 
 
Dilated Cardiomyopathy is characterized by the 
systolic dysfunction and the left ventricular (LV) 
dilatation with the progressive LV failure. Although this 
disease has various etiopathogenesis, the term 
cardiomyopathy refers to genetic cardiomyopathy.  Baig 
et al showed that the patient with DCM have a familiar 
DCMfor 48% of cases, when asymptomatic LV 
dysfunction was considered the first sign on DCM [1-3]. 
The familiar screening is strongly recommended in 
familiar of patients with DCM [4]. However the role of 
genetic test is unclear. 
 Genetic test for dilated Cardiomyopathy.More 
than 30 genes have been identified as cause of DCM 
showing a marked locus heterogeneity. The genes 
implicated encode proteins involved in the structure of the 
cardiomyocyte as cytoskeletal proteins, myofilament 
proteins and ion channels. Mitochondrial defects have also 
been identified(Table 1)[5]. This heterogeneity highlights 
the various mechanisms involved in DCM. This disease is 
likely final phenotype of reduced contractile force of 
cardiomyocytes. Interestingly, some mutations of the 
genes causing DCM can cause also hypertrophic 
cardiomyopathy (HCM), clarifying the importance of 
secondary factors as modifiers genes and environment to 
determine the phenotype. Most genetic DCM inheritance 
follows an autosomal dominant pattern, although X-
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Gene Protein Function 
ACTC cardiac actin Sarcomeric protein; muscle contraction 
DES desmin DAGC; transduces contractile forces 
SGCD δ-sarcoglycan DAGC; transduces contractile forces 
MYH7 β-myosin heavy chain Sarcomeric protein; muscle contraction 
TNNT2 cardiac troponin T Sarcomeric protein; muscle contraction 
TPM1 α-tropomyosin Sarcomeric protein; muscle contraction 
TTN titin Sarcomere structure/extensible scaffold for  proteins 
VCL metavinculin Sarcomere structure; intercalated discs 
MYBPC3 myosin-binding protein C Sarcomeric protein; muscle contraction 
MLP/CSRP3 muscle LIM protein Sarcomere stretch sensor/ Z discs 
ACTN2 α-actinin-2 Sarcomere structure; anchor for myofibrillar actin 
PLN phospholamban 
Sarcoplasmic reticulum Ca++ regulator; 
inhibits SERCA2 pump 
ZASP/LDB3 Cypher 
Cytoskeletal assembly; targeting/clustering of 
membrane proteins 
MYH6 α-myosin heavy chain Sarcomeric protein; muscle contraction 
ABCC9 SUR2A 
Kir6.2 regulatory subunit, inwardly rectifying 
cardiac KATP channel 
TNNC1 cardiac troponin C Sarcomeric protein; muscle contraction 
titin-cap TCAP titin-cap or telethonin Z-disc protein that associates with titin; aids sarcomere assembly 
TNNI3 cardiac troponin I sarcomeric protein, muscle contraction; also seen as recessive 
EYA4 eyes-absent 4 Transcriptional coactivators (Six and Dach) 
TMPO thymopoietin Also LAP2; a lamin-associated nuclear protein 
PSEN1/2 presenilin 1 / 2 Transmembrane proteins, gamma secretase activity 
CRYAB alpha B crystalin Cytoskeletal protein 
PDLIM3 PDZ LIM domain protein 3 Cytoskeletal protein 
MYPN myopalladin Sarcomeric protein, z-disc 
LAMA4 laminin a-4 Extracellular matrix protein 
ILK integrin-linked kinase Intracellular ser-threo kinase; interacts with integrins 
RBM20 RNA binding protein 20 RNA binding protein of the spliceosome 
LMNA lamin A/C Structure/stability of inner nuclear membrane 
SCN5A sodium channel Controls sodium ion flux 
DMD dystrophin DAGC; transduces contractile force 
 
 
Table 1. Dilated Cardiomyopathy (DCM): genes mutated in DCM. 
The most common genes mutated in DCM and the proteins that they codified for. Modified from: Hershberger RE, Morales 
A, Siegfried JD. Clinical and Genetic Issues in Dilated Cardiomyopathy: a Review for Genetics Professionals. Genet Med 2010; 12(11): 655-67. 
linked, recessive, and mitochondrial patterns of 
inheritance occur. The sensitivity of genetic is estimated at 
20% and none of genes appears to account for 5% of 
familial DCM. This low sensitivity is very important and 
it underlines the little diagnostic power of genetic 
testingin not-selected people. The sensitivity is higher in 
specific forms as the DCMs associated with conduction 
defects. Genetic DCM shows age-dependent penetrance 
and a variable expression. The same mutation can result in 
a different phenotype  in members of the same family, 
underlying the importance of others factors [6]. Some 
mutations are more aggressive and they can often cause 
sudden death, e.g. mutations of  laminin and desmin [7]. 
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 Patients with a clinical diagnosis of DCMand 
significant cardiac conduction disease  and/or a 
family history of premature unexpected sudden death 
have been recommended for a comprehensive or 
targeted (LMNA and SCN5A) DCM genetic testing. 
 
 Family members and appropriate relatives of an index 





 Patients with familial DCM have been recommended 
for genetic testing to confirm thediagnosis, to 
recognize those who are at highest risk of arrhythmia 
and syndromic features, to facilitate cascade 
screening within the family, and to help with family 
planning. 
 
Table 2.Recommendations to genetic testing in Dilated 
Cardiomyopathy.  
Modified from HRS/EHRA Expert Consensus Statement on the 
State of Genetic Testing for the Channelopathies and 
Cardiomyopathies [16] 
 
When the mutation of the proband is known, the 
family genetic screening is very helpful to diagnose 
eventual early DCM. However clinicians should always 
keep in mind that, considered the heterogeneity of 
expression, some carriers would never develop the 
disease.  The family screening is mandatory for the 
aggressive gene-mutations as mutations of laminin. Indeed 
the gene testing changes prognosis only for laminin 
mutations. In conclusion, clinically the genetic testing is 
recommended only for family screening and especially for 
aggressive mutations (table 2). However, it is very 
important to evaluate the mutations for research purposes, 
especially for possible gene therapy in future. 
 
STATE OF GENETIC TESTING FOR HYPERTROPHIC 
CARDIOMYOPATHY (HCM) 
Class I  
 
 Patients with a clinical diagnosis of HCM based on 
examination of the patient’s clinical history, family 
history, and electrocardiographic echocardiographic 
phenotype have been recommended for a 
comprehensive or targeted (MYBPC3, MYH7, 
TNNI3, TNNT2, TPM1) HCM genetic testing 
 
 Family members and appropriate relatives of an index 
case have been recommended for a mutation-specific 
genetic testing. 
 
Table 3.Recommendations to genetic testing for 
Hypertrophic Cardiomyopathy. 
Modified from HRS/EHRA Expert Consensus Statement 
on the State of Genetic Testing for the Channelopathies 
and Cardiomyopathies [16] 
 
III.  HYPERTROPHIC CARDIOMYOPATHY 
 
Hypertrophic cardiomyopathy (HCM) is a 
common disease, that affects 1 in 500 people [8]. Usually 
it is inherited as an autosomal dominant trait, insteadde 
novo mutations are rare [9]. The phenotype of a patient 
with HCM is characterized by asymmetrical cardiac 
hypertrophy, that doesn’t have any evident cause, myocyte 
disarray, and fibrosis. Patients show a marked phenotypic 
variability, even within the same family, and an 
incomplete penetrance [8]. HCM is one of the most 
frequently identified causes of sudden cardiac death 
caused by the high prevalence of malignant arrhythmias. 
Althoughmanypatients with HCM are asymptomatic and 
sudden death may be unpredictable, genetic screening in 
families is essential for prevention. Mutations in MYH7 
and MYBPC3 genes, that encod for the beta-myosin 
heavy chain and the cardiac myosin binding protein-C, are 
present in about 80% of HCM cases [10,11]. Mutations in 
other genes, such as TNNT2, TNNI3, and TPM1, encod 
for proteins of the troponin complex and occur in 10% to 
15% of HCM patients [12]. 9 genes are used for genetic 
testing. Considering all genetic testing these 9 genes, a 
mutation is identified in 40% to 60% of sporadic and 
familial cases[10]. Anyway, the relation between 
genotype and phenotype remains elusive, because of 
extreme genetic heterogeneity, variation in penetrance and 
expressivity, even considering individuals carrying 
identical mutations. Cases with a negative HCM genetic 
test might have HCM-causing mutations in unexplored 
regions within the known HCM genes or in undiscovered 
genes. 
Rarely the phenotype is related to underlying 
HCM disease gene, and so it might bepoorlyuseful for 
managing patients. Mutations in MYH7 alleles usually are 
associated with an important clinical disease expression. 
Instead, mutations in MYBPC3 alleles have been 
associated with later onset disease [13]. Patients with 
TNNT2 mutations usually show a lower severity of LV 
hypertrophy but a higher arrhythmia risk [14]. Only few 
specific mutations might carry a prognostic implication. 
That is the reason why a genetic test result in isolation will 
not constitute an indication for an ICD for primary 
prevention. 
In conclusion, genetic testing is recommended for 
patients with a clinical diagnosis of HCM when the 
genetic testing benefit family members and potentially 
other relatives (table 3). It is recommended in families 
with a history of sudden death, in families in which 
numerous relatives are at risk and that need periodic 
clinical evaluation without the genetic testing, and when 
the clinical diagnosis is difficult. It might be 
recommended even thegenetic analysis of post mortem 
samples if there is a case ofsudden deathin a family where 
HCM was not previously known. Family screening is 
recommended for all first-degree relatives and it is 
important also for cost-effectiveness reasons. Indeed, 
when a family member has anegative genetic testing 
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result, he/she can be discharged and there is no reason for 
clinical investigations or long-term follow-up [15]. Long-
term studies are required to accumulate reliable evidence 
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